News & Updates
Filter by Specialty:

IBD patients at high myocarditis risk for up to 20 years
The risk of myocarditis appears to be elevated among patients with inflammatory bowel disease (IBD) for ≥20 years following diagnosis, suggests a study in Sweden. However, absolute risks remain low.
IBD patients at high myocarditis risk for up to 20 years
21 Sep 2024
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
According to patient-reported outcomes (PROs) from the TROPiCS-02 study, sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) chemotherapy is associated with health-related quality of life (HRQoL) benefits across most symptoms and functioning domains among patients with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
21 Sep 2024
Depemokimab a safe remedy for severe asthma exacerbations
Treatment with depemokimab results in a substantial decrease in exacerbations, with an acceptable safety profile, among severe asthma patients with an eosinophilic phenotype, results of the SWIFT-1 and 2 studies have shown.